John H. Healey
Memorial Sloan Kettering Cancer Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by John H. Healey.
Cancer | 1998
Cristina R. Antonescu; Pedram Argani; Robert A. Erlandson; John H. Healey; Marc Ladanyi; Andrew G. Huvos
Skeletal myxoid chondrosarcoma (SMC) is considered to be either a typical chondrosarcoma with prominent myxoid alterations or an altogether unique malignant cartilage tumor. Extraskeletal myxoid chondrosarcoma (EMC) is a relatively rare but well‐recognized neoplasm. It was initially thought to be a low grade sarcoma of cartilage derivation and was recently found, in most cases, to contain a reciprocal t(9;22), resulting in a fusion of the EWS and CHN genes. Are SMC and EMC the same entity arising in two different locations, or are they two separate entities? To the authors knowledge, this study represents the first systematic attempt to answer this question.
Cancer | 2000
Enrique de Alava M.D.; Cristina R. Antonescu; Angel Panizo; Denis H. Y. Leung; Paul A. Meyers; Andrew G. Huvos; F. Javier Pardo-Mindán; John H. Healey; Marc Ladanyi
Disease stage at the time of diagnosis and response to therapy are the main prognostic factors for patients with Ewing sarcoma or peripheral neuroectodermal tumor (ES/PNET). The primary genetic alteration in ES/PNET, the fusion of the EWS gene with FLI1 or ERG, is diagnostically highly specific for these tumors, and molecular variation in the structure of the EWS‐FLI1 fusion gene also is of prognostic significance. In contrast, secondary genetic alterations, such as P53 alterations, are relatively uncommon in ES/PNET, and their prognostic impact has not been extensively studied.
Cancer | 1998
Akira Kawai; John H. Healey; Patrick J. Boland; Patrick P. Lin; Andrew G. Huvos; Paul A. Meyers
Treatment of malignant tumors of the pelvis represents one of the most difficult problems in musculoskeletal oncology. However, factors that influence the local and systemic control of the disease remain ill‐defined.
Cancer | 2000
Jay S. Wunder; John H. Healey; Aileen M. Davis; Murray F. Brennan
Staging systems for soft tissue sarcoma (STS) are important to identify patients with similar systemic risk who might benefit from specific treatments. This study compared four commonly used staging systems for predicting systemic outcomes of patients with localized extremity STS, as proposed by the fourth and fifth editions of the American Joint Committee on Cancer/International Union Against Cancer (AJCC/UICC) staging system, the Memorial Sloan‐Kettering Cancer Center (MSK) system, and the Surgical Staging System (SSS) of the Musculoskeletal Tumor Society.
Cancer | 1998
Patrick P. Lin; Karen D. Schupak; Patrick J. Boland; Murray F. Brennan; John H. Healey
Surgical resection and adjuvant radiation therapy are standard therapy for soft tissue sarcomas. When the tumor approximates bone, periosteal excision may be necessary. It was hypothesized that periosteal stripping and radiation therapy would increase the rate of pathologic fracture.
Cancer | 2000
Guo Wei M.D.; Cristina R. Antonescu; Enrique de Alava; Denis H. Y. Leung; Andrew G. Huvos; Paul A. Meyers; John H. Healey; Marc Ladanyi
The primary genetic alteration in > 95% of Ewing sarcomas (ES) is a specific fusion of EWS with FLI1 or ERG. Secondary genetic alterations possibly involved in progression of ES are not well understood. A recent study found loss of the negative cell cycle regulator gene INK4A in 8 of 27 ES samples (30%). To confirm these findings and evaluate their prognostic significance, the authors studied INK4A deletion in 41 ES samples from 39 patients.
Cancer | 2003
Caroline Laverdiere; E. Anders Kolb; Jeffrey G. Supko; Richard Gorlick; Paul A. Meyers; Robert G. Maki; Leonard Wexler; George D. Demetri; John H. Healey; Andrew G. Huvos; Allen M. Goorin; Rochelle Bagatell; Ana Ruiz-Casado; Cecilia Guzman; Jose Jimeno; David Harmon
Recurrent osteosarcoma is a drug‐resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET‐743) as a salvage therapy in these patients.
Cancer | 1994
Hideki Yoshikawa M.D.; Wolfgang J. Rettig; Joseph M. Lane; Kunio Takaoka; Edward Alderman; Bonita Rup; Vicki Rosen; John H. Healey; Andrew G. Huvos; Pilar Garin-Chesa
Background. Bone morphogenetic proteins (BMPs) are potent inducers of bone formation. Functional and immunohistochemical studies have identified BMPs in a subset of osteosarcomas. In the present study, the authors extend the analysis of BMP expression to other bone and soft tissue sarcomas.
Cancer | 1994
Ralph C. Marcove; Dhiren S. Sheth; Earl W. Brien; Andrew G. Huvos; John H. Healey
Background. Giant cell tumors (GCTs) of the sacrum are a difficult clinical problem. Wide excision (total sacrectomy) is associated with high morbidity and pelvic/spinal instability. Curettage with or without supplemental radiotherapy is associated with a high recurrence rate. In view of the proven effectiveness of cryosurgery as an adjunct to curettage for extremity GCT, cryosurgery was used for treatment of GCTs of the sacrum.
Cancer | 2000
John H. Healey; Holly K. Brown
Patients with metastatic disease to the bone present a management challenge. Of the complications encountered in these patients, the predominant types that require surgical intervention are pathologic or impending fractures and neurologic compromise secondary to cord compression from spinal metastases. A multimodality approach is helpful in caring for these patients, and addressing complications related to bony metastatic disease with timely and appropriate intervention is an important step in optimizing care and quality of life.